MedTrace Logo

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-12-18

Study results available
· View outcomes & findings →

Summary

Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular function and tests of bone health.

Conditions

Interventions

DRUG

Tenofovir/emtricitabine

Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine

DRUG

Tenofovir/emtricitabine/efavirenz

Continued therapy with tenofovir/emtricitabine/efavirenz

DRUG

Raltegravir

Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine

Sponsors & Collaborators

Principal Investigators

  • Samir K Gupta, MD, MS · Indiana University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-10-31
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270802 on ClinicalTrials.gov